Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
I
086890
vs
K
KOSPI 200
Over the past 12 months, Isu Abxis Co Ltd has underperformed KOSPI 200, delivering a return of -33% compared to KOSPI 200's +50% growth.
Stocks Performance
086890 vs KOSPI 200
Performance Gap
086890 vs KOSPI 200
Performance By Year
086890 vs KOSPI 200
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Isu Abxis Co Ltd
Glance View
Isu Abxis is a Korean biotech company that develops antibody-based medicines and diagnostic products. Its core work is in making monoclonal antibodies and related biotech tools used in cancer and other disease research, plus some finished products for medical and lab use. In simple terms, it sits between drug discovery and the companies or labs that need those biologic products. The company sells products and services to pharmaceutical partners, hospitals, research labs, and other healthcare customers. It makes money by selling diagnostic reagents and research materials, and by advancing drug candidates through development deals, licensing, and other partnership arrangements. That means part of its business comes from products on the market, while another part depends on turning its research pipeline into partner-funded programs. What makes Isu Abxis different is that it is not a broad healthcare company or a drugstore chain. It is a specialized biotech supplier and developer focused on antibodies, which are useful both as medicines and as tools for testing and research. That gives it a dual role: it helps other companies and labs do their work today, while also trying to turn its own science into future therapies.